Preventing Anthracycline-Associated Heart Failure: What Is the Role of Dexrazoxane?: <i>JACC</i>: CardioOncology Controversies in Cardio-Oncology.

10 Concerns regarding secondary malignancies, such as acute myeloid leukemia and brain tumors, have been reported only in pediatric patients, with a slight trend favoring the control group. 10 Furthermore, there is a consideration that dexrazoxane may exacerbate myelosuppression caused by chemotherapeutic agents, as evidenced by a lower nadir in white blood cell count in the dexrazoxane group, although no significant differences were observed in the incidence rates of thrombocytopenia, neutropenia, and anemia. 10 Overall, the totality of available evidence robustly supports the use of dexrazoxane in adult patients at high risk for developing AIC.

also in 2,235 other papers